Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical needs. The company’s primary areas of focus include HIV, AIDS, liver disease, oncology and serious cardiovascular and respiratory conditions.
The company acquired Kite Parma in the first quarter of 2018. Kite Parma develops a drug called Yescarta, which is a cancer treatment that is used by way of eliminating cancer cells through an immunisation process.
Gilead recently reported their earnings for the first quarter of 2019. Revenue grew by 3.8% to $5.2bn (2018: $5bn), operating income increased by 3.9% to $2.237bn (2018: $2.153bn) and diluted earnings per share rose by 31.6% to $1.54 per share.
Click here to download the full report.